Cooper Companies (NASDAQ:COO) Posts Quarterly Earnings Results

Cooper Companies (NASDAQ:COO) issued its earnings results on Thursday. The medical device company reported $1.21 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.10 by $0.11, FiscalAI reports. Cooper Companies had a return on equity of 10.34% and a net margin of 9.67%.The firm had revenue of $1.08 billion for the quarter, compared to analyst estimates of $1.05 billion. During the same period in the previous year, the company posted $0.96 earnings per share. The business’s revenue was up 7.9% on a year-over-year basis. Cooper Companies updated its FY 2026 guidance to 4.580-4.660 EPS.

Here are the key takeaways from Cooper Companies’ conference call:

• Record Q2 results came in ahead of expectations, with revenue up 8% to $1.08 billion and non-GAAP EPS up 26% to $1.21, marking the company’s tenth straight quarter of beating consensus.
• CooperSurgical strategic review is advancing after settlements resolved substantially all embryo media recall claims, and management said it is now in active discussions with multiple interested parties about the business.
• CooperVision strength was offset by Asia-Pac weakness: Americas and EMEA grew well, but Asia-Pac declined as the company continued to rationalize legacy hydrogel products and faced softer demand in Japan and China.
• Fertility performed strongly, with CooperSurgical fertility revenue up 10% organically, driven by capital equipment, RI Witness, and broader product demand; management expects mid-single-digit growth in the back half of the year.
• Free cash flow outlook improved to about $650 million for fiscal 2026, supported by inventory reductions from a new AI-based control system, though gross margins are expected to face pressure from FX, tariffs, freight, and lower production.

Cooper Companies Price Performance

Cooper Companies stock opened at $62.02 on Friday. Cooper Companies has a 52 week low of $58.89 and a 52 week high of $89.83. The business has a 50-day simple moving average of $65.17 and a 200 day simple moving average of $74.57. The company has a quick ratio of 0.79, a current ratio of 1.34 and a debt-to-equity ratio of 0.22. The stock has a market cap of $12.10 billion, a price-to-earnings ratio of 30.70, a PEG ratio of 1.56 and a beta of 0.87.

Analysts Set New Price Targets

A number of analysts recently issued reports on the company. Citigroup reiterated a “neutral” rating and set a $69.00 price objective (down from $80.00) on shares of Cooper Companies in a research note on Thursday, May 28th. Rothschild & Co Redburn lowered Cooper Companies from a “buy” rating to a “neutral” rating and set a $85.00 price objective on the stock. in a research note on Wednesday, March 4th. Needham & Company LLC boosted their price objective on Cooper Companies from $99.00 to $101.00 and gave the company a “buy” rating in a research note on Friday, March 6th. Piper Sandler set a $86.00 price objective on Cooper Companies and gave the company an “overweight” rating in a research note on Monday. Finally, Wall Street Zen upgraded Cooper Companies from a “hold” rating to a “buy” rating in a research note on Saturday, February 28th. One analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, six have given a Hold rating and two have assigned a Sell rating to the stock. According to data from MarketBeat, the company has an average rating of “Hold” and a consensus price target of $87.00.

Cooper Companies News Summary

Here are the key news stories impacting Cooper Companies this week:

• Positive Sentiment: Cooper Companies reported fiscal second-quarter EPS of $1.21, beating the $1.10 consensus, while revenue of $1.08 billion also topped estimates and rose 7.9% year over year. Cooper Companies earnings transcript
• Positive Sentiment: The company also reaffirmed growth momentum by posting improved profitability, with net margin of 9.67% and return on equity of 10.34%, which should support investor confidence. Cooper Companies press release
• Neutral Sentiment: Management guided fiscal 2026 EPS to $4.58-$4.66, which is close to the analyst view of $4.62 and suggests the outlook was acceptable, but not a major upside surprise. Cooper Companies stock page
• Neutral Sentiment: Several earnings-preview articles published ahead of the report likely added attention, but the main stock driver today appears to be the actual results and guidance. Yahoo Finance preview

Hedge Funds Weigh In On Cooper Companies

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Cresset Asset Management LLC grew its stake in Cooper Companies by 7.5% in the third quarter. Cresset Asset Management LLC now owns 4,393 shares of the medical device company’s stock worth $301,000 after purchasing an additional 306 shares in the last quarter. Captrust Financial Advisors grew its stake in Cooper Companies by 10.0% in the second quarter. Captrust Financial Advisors now owns 3,500 shares of the medical device company’s stock worth $249,000 after purchasing an additional 317 shares in the last quarter. Snowden Capital Advisors LLC grew its stake in Cooper Companies by 10.0% in the second quarter. Snowden Capital Advisors LLC now owns 4,088 shares of the medical device company’s stock worth $291,000 after purchasing an additional 373 shares in the last quarter. Public Employees Retirement System of Ohio grew its stake in Cooper Companies by 0.6% in the third quarter. Public Employees Retirement System of Ohio now owns 62,229 shares of the medical device company’s stock worth $4,266,000 after purchasing an additional 386 shares in the last quarter. Finally, Arkadios Wealth Advisors grew its stake in Cooper Companies by 14.3% in the fourth quarter. Arkadios Wealth Advisors now owns 3,552 shares of the medical device company’s stock worth $291,000 after purchasing an additional 444 shares in the last quarter. 24.39% of the stock is currently owned by hedge funds and other institutional investors.

Cooper Companies Company Profile

Cooper Companies, Inc (NASDAQ: COO) is a global medical device company headquartered in San Ramon, California. Founded in 1958, the company has grown through strategic acquisitions and organic development to become a major provider of vision care and women’s health products. Cooper Companies operates through two primary business segments—CooperVision and CooperSurgical—each serving specialized markets within the healthcare industry.

The CooperVision segment develops, manufactures and markets a broad range of soft contact lenses, as well as related accessories.